MERIT-HF


Also found in: Acronyms.

MERIT-HF

Metoprolol CR/XL Randomised Intervention Trial in Heart Failure. A clinical trial which reported a major reduction in cardiovascular morbidity and mortality in patients treated with the beta-adrenegic blocking agent metoprolol.
Mentioned in ?
References in periodicals archive ?
The MERIT-HF findings showed that beta-blockade had a marked benefit on survival in heart failure patients.
In MERIT-HF comparing Toprol-XL to placebo in daily doses up to 200 mg once daily, 10.
While the outcomes data in MERIT-HF were impressive, the target dosage for metoprolol was 200 mg/day.
A statistically and clinically significant decrease in mortality was reported in CIBIS-II, US Carvedilol, and MERIT-HF.
3,11-14] Both MERIT-HF and CIBIS-II reported significant decreases in sudden death in patients receiving [Beta]-blocker therapy.
6% and 17% of the MERIT-HF and CIBIS-II study populations, respectively.
3,12,13] US Carvedilol demonstrated a statistically significant decrease in mortality in patients with nonischemic heart failure receiving [Beta]-blocker therapy,[13] while MERIT-HF and CIBIS-II did not.
In MERIT-HF, adding metoprolol to standard triple-drug therapy saved an extra four lives per 100 treated patients per year.
It's also entirely appropriate to prescribe these agents in patients with asymptomatic left ventricular dysfunction, even though such patients weren't included in MERIT-HF or the other large trials.
Drug detail people and experts with industry ties succeeded in alarming physicians by emphasizing [beta]-blockers' reported side effects, but MERIT-HF shows how overblown the side effect rhetoric has been, he said.